Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.0952
-0.0036 (-3.64%)
At close: Mar 3, 2026, 4:00 PM EST
0.0952
0.00 (0.00%)
Pre-market: Mar 4, 2026, 8:15 AM EST
Quince Therapeutics Stock Forecast
QNCX's stock price has decreased by -93.43% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Quince Therapeutics stock has a target of 10, which predicts a 10,404.20% increase from the current stock price of 0.1.
Price Target: $10 (+10,404.20%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 24, 2025.
Analyst Ratings
The average analyst rating for Quince Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +5,152.10% | Jan 29, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +5,152.10% | Dec 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +4,101.68% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -1.31
EPS Next Year
-0.93
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.14 | -0.64 | |||
| Avg | -1.15 | -0.93 | |||
| Low | -1.14 | -1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.